2 results
Approved WMOCompleted
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 60 mgor 100 mg versus placebo for 12 weeks on the percent change from baseline in low-densitylipoprotein cholesterol (LDL-C) in patients with HeFH.The…
Approved WMORecruiting
Primary:To evaluate the efficacy and safety of Ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK tyrosine kinase inhibitor (TKI).Secondary:To obtain additional…